Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01049789 · ClinicalTrials.gov registry record · NA

Treatment for Depression Among HIV-Infected Youth

A NA study of Depression and HIV Infections, sponsored by University of North Carolina, Chapel Hill.

Completed
Registry status
NA
Development phase
42
Enrollment target
4
Study locations

NCT01049789: Completed NA study of Depression and HIV Infections, sponsored by University of North Carolina, Chapel Hill.

NCT01049789 is a NA study of Depression and HIV Infections that has completed, run by University of North Carolina, Chapel Hill. The registered enrollment target is 42 participants, below the 786-participant average among 679 other Depression trials with a reported enrollment target (95% lower). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01049789, a NA study of Depression and HIV Infections, has completed, sponsored by University of North Carolina, Chapel Hill.

COMPLETED
Registry status
NA
Development phase
42 participants
Enrollment target
4
Study locations

Study Summary

This is a two-phase study that is designed to test a novel behavioral intervention to treat depression in Human Immunodeficiency Virus (HIV) adolescents and young adults. Four Adolescent Trials Network (ATN) sites will be assigned to either the Combination Cognitive Behavioral Therapy and Medication Management (COMB) treatment group or the Treatment as Usual (TAU) group. Phase I involves pilot testing of a 24-week intervention consisting of Cognitive Behavioral Therapy (CBT) and Medication Management (MM) manuals at sites assigned to the COMB treatment group. Participants enrolled at TAU sites will receive treatment for depression that is typical at that site, which may include medication management, psychosocial therapy, or a combination of the two. Psychopharmacological and psychosocial interventions will not be standardized and participants may receive any depression treatment recommended by the site clinicians while on study. Study coordinators and site clinicians, regardless of group assignment, will document depression symptoms and treatment regimens for all participants for 24 weeks. In addition, site staff and participants at COMB sites will participate in an exit interview. The findings from these interviews will be used to revise both CBT and MM intervention manuals at the end of Phase I. Phase II is a feasibility study of the revised CBT and MM manuals. Phase II involves similar procedures as Phase I; sites assigned to COMB will implement the revised CBT and MM manuals. Participants at TAU sites will receive treatment for depression that is typical at that site. As in Phase I, psychopharmacological and psychosocial interventions will not be standardized and participants may receive any depression treatment recommended by the site clinicians while on study. Depression symptoms and treatment regimens for all participants will be documented for 24 weeks. Additionally, all Phase II participants will have 2 follow-up visits at weeks 36 and 48. Again, site st

Conditions Studied

Depression HIV Infections HIV

Interventions

  • BEHAVIORAL COMB - Combination Cognitive Behavioral Therapy and Medication Management
  • BEHAVIORAL TAU - Treatment as Usual

Study Locations (4)

Florida

  • USF College of Medicine - Tampa

New York

  • Montefiore Medical Center - The Bronx

Pennsylvania

  • The Childrens Hospital of Philadelphia - Philadelphia

Tennessee

  • St. Jude Children's Research Center - Memphis

Trial Details

FieldValue
Enrollment Target 42 participants
Start Date 2010-06
Est. Completion 2013-10
Phase NA
University of North Carolina, Chapel Hill

1,109 total trials

What the finished NCT01049789 record still lists

NCT01049789 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 42 participants, a relatively small participant target, below the 786-participant average among 679 other Depression trials with a reported enrollment target (95% lower).

The record links to 3 conditions, with Depression appearing as the primary indexed condition, and to 2 interventions - of which COMB - Combination Cognitive Behavioral Therapy and Medication Management is the first listed.

NCT01049789 reports a single indexed study location in Florida, New York, Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT01049789 about?

NCT01049789 is a clinical study titled "Treatment for Depression Among HIV-Infected Youth". This is a two-phase study that is designed to test a novel behavioral intervention to treat depression in Human Immunodeficiency Virus (HIV) adolescents and young adults. Four Adolescent Trials Network (ATN) sites will be assigned to either the Combination Cognitive Behavioral Therapy and Medication...

What is the current status of trial NCT01049789?

This trial is currently completed. It is a NA study. The enrollment target is 42 participants. The study started on 2010-06. Estimated completion is 2013-10.

What conditions does trial NCT01049789 study?

This clinical trial studies the following conditions: Depression, HIV Infections, HIV.

What interventions are being tested in trial NCT01049789?

The interventions under investigation include: COMB - Combination Cognitive Behavioral Therapy and Medication Management (BEHAVIORAL), TAU - Treatment as Usual (BEHAVIORAL).

Who is sponsoring clinical trial NCT01049789?

This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01049789 being conducted?

This trial has 4 study locations across Florida, New York, Pennsylvania, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Depression

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01049789's enrollment target sits among peer trials

42 501st of 679 higher than 175 of 679 other Depression trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Depression trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02852213 · 42 participants · Phase 1

    A Single-Stage, Adaptive, Open-label, Dose Escalation Safety and Efficacy Study of AADC Deficiency in Pediatric Patients

  • NCT03136146 · 42 participants · Phase 2

    Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia

  • NCT03178149 · 42 participants · Phase 1

    A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration

  • NCT03663530 · 42 participants · NA

    Circadian Misalignment and Energy Balance

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT01049789, the US trial registry maintained by the National Library of Medicine. NCT01049789 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.